{
    "hands_on_practices": [
        {
            "introduction": "This exercise provides a foundational skill in pharmacology: interpreting experimental data to understand how tolerance manifests. By analyzing concentration-effect curves before and after chronic drug exposure, you will learn to distinguish between changes in a drug's potency ($EC_{50}$) and its efficacy ($E_{max}$), allowing you to pinpoint the nature of the pharmacodynamic tolerance. This practice is crucial for connecting theoretical models to real-world observations .",
            "id": "4944934",
            "problem": "A receptor-mediated analgesic is studied at steady state on day $1$ (before tolerance) and day $14$ (after repeated dosing). At each time point, plasma concentration $C$ (in mg/L) is measured concurrently with effect $E$ (in arbitrary units), and the drug exhibits a saturable concentration–effect relationship consistent with a receptor model. The following paired observations are obtained:\n\n- Day $1$: $(C, E)$ pairs: $(0.5, 20)$, $(2, 50)$, $(10, 83)$, $(50, 96)$, $(200, 99)$\n- Day $14$: $(C, E)$ pairs: $(0.5, 8)$, $(2, 25)$, $(10, 63)$, $(50, 89)$, $(200, 97)$\n\nAssume the concentration–effect relationship can be represented by a sigmoidal model in which $E$ approaches a maximum at high $C$, and that the data were collected under conditions where concentrations are directly measured (so dosing and pharmacokinetics do not need to be inferred). Using only first principles and core definitions of potency (the concentration required to achieve a specified fraction of maximal effect) and efficacy (the maximal achievable effect), determine which tolerance model best explains the day $14$ changes relative to day $1$.\n\nA. Tolerance decreases $E_{max}$ while $EC_{50}$ is unchanged.\n\nB. Tolerance increases $EC_{50}$ while $E_{max}$ is unchanged.\n\nC. Tolerance decreases the Hill coefficient $n$ while $E_{max}$ and $EC_{50}$ are unchanged.\n\nD. Tolerance is purely pharmacokinetic (increased clearance), with no change in pharmacodynamics; the observed shift arises from lower concentrations at equal doses.",
            "solution": "## PROBLEM VALIDATION\n\n### Step 1: Extract Givens\n- **Drug Type and Model**: A receptor-mediated analgesic with a saturable, sigmoidal concentration–effect ($C$–$E$) relationship.\n- **Time Points**: Measurements are taken at steady state on day $1$ (before tolerance) and day $14$ (after repeated dosing).\n- **Measured Variables**: Plasma concentration $C$ (in mg/L) and effect $E$ (in arbitrary units).\n- **Day 1 Data**: $(C, E)$ pairs: $(0.5, 20)$, $(2, 50)$, $(10, 83)$, $(50, 96)$, $(200, 99)$.\n- **Day 14 Data**: $(C, E)$ pairs: $(0.5, 8)$, $(2, 25)$, $(10, 63)$, $(50, 89)$, $(200, 97)$.\n- **Assumption**: Concentrations are directly measured. No inference about pharmacokinetics is required.\n- **Task**: Determine the tolerance model by comparing the pharmacodynamic parameters on day $14$ relative to day $1$, based on the definitions of potency and efficacy.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientific Grounding**: The problem is scientifically grounded. It uses the standard sigmoidal Emax model (Hill equation) to describe the concentration-effect relationship, a cornerstone of pharmacology. The concepts of tolerance, efficacy ($E_{max}$), and potency ($EC_{50}$) are fundamental and correctly applied.\n- **Well-Posedness**: The problem is well-posed. It provides two sets of concentration-effect data, from which the pharmacodynamic parameters can be estimated. The question asks for a comparison of these parameters, which leads to a unique conclusion about the type of tolerance observed.\n- **Objectivity**: The problem is stated objectively using quantitative data and established scientific terminology. There is no ambiguity or subjective language.\n- **Conclusion**: The problem is valid. It is a standard, well-formulated problem in quantitative pharmacology.\n\n## SOLUTION DERIVATION\n\nThe relationship between concentration $C$ and effect $E$ is described by the sigmoidal Hill equation:\n$$E(C) = \\frac{E_{max} \\cdot C^n}{EC_{50}^n + C^n}$$\nwhere:\n- $E_{max}$ is the maximum possible effect (efficacy).\n- $EC_{50}$ is the concentration required to produce $50\\%$ of the maximum effect. It is a measure of the drug's potency (potency is inversely related to $EC_{50}$).\n- $n$ is the Hill coefficient, which describes the steepness of the concentration-effect curve.\n\nWe must estimate these parameters for both day $1$ and day $14$ to characterize the change due to tolerance.\n\n### Analysis of Day 1 Data\nThe data points are $(0.5, 20)$, $(2, 50)$, $(10, 83)$, $(50, 96)$, $(200, 99)$.\n\n1.  **Estimate $E_{max,1}$ (Efficacy)**: As the concentration $C$ increases to very high values ($50$ mg/L and $200$ mg/L), the effect $E$ approaches a plateau. The values $96$ and $99$ strongly suggest that the maximum effect, $E_{max,1}$, is approximately $100$ arbitrary units.\n\n2.  **Estimate $EC_{50,1}$ (Potency)**: The $EC_{50}$ is the concentration at which $E = 0.5 \\cdot E_{max}$. With $E_{max,1} \\approx 100$, we look for the concentration that gives an effect of $E=50$. The data explicitly provides the point $(2, 50)$. Therefore, we can directly estimate $EC_{50,1} = 2$ mg/L.\n\n3.  **Estimate Hill Coefficient $n_1$**: Let's test if a simple Michaelis-Menten model (where $n=1$) fits the data with $E_{max,1} = 100$ and $EC_{50,1} = 2$.\n    The model is $E(C) = \\frac{100 \\cdot C}{2 + C}$.\n    - For $C=0.5$: $E = \\frac{100 \\cdot 0.5}{2 + 0.5} = \\frac{50}{2.5} = 20$. (Matches data)\n    - For $C=10$: $E = \\frac{100 \\cdot 10}{2 + 10} = \\frac{1000}{12} \\approx 83.3$. (Matches data value of $83$)\n    - For $C=50$: $E = \\frac{100 \\cdot 50}{2 + 50} = \\frac{5000}{52} \\approx 96.2$. (Matches data value of $96$)\n    - For $C=200$: $E = \\frac{100 \\cdot 200}{2 + 200} = \\frac{20000}{202} \\approx 99.0$. (Matches data value of $99$)\n    The fit is excellent, confirming our parameters for Day 1: $E_{max,1} \\approx 100$, $EC_{50,1} = 2$ mg/L, and $n_1 \\approx 1$.\n\n### Analysis of Day 14 Data\nThe data points are $(0.5, 8)$, $(2, 25)$, $(10, 63)$, $(50, 89)$, $(200, 97)$.\n\n1.  **Estimate $E_{max,2}$ (Efficacy)**: As $C$ increases to $200$ mg/L, the effect is $97$. This value is very close to the maximum effect observed on day $1$. It is reasonable to conclude that the maximum effect is unchanged, so $E_{max,2} \\approx 100$ arbitrary units.\n\n2.  **Estimate $EC_{50,2}$ (Potency)**: We look for the concentration where $E = 0.5 \\cdot E_{max,2} \\approx 50$.\n    On day $14$, at $C=2$, the effect is only $25$. At $C=10$, the effect is $63$. The concentration required to produce an effect of $50$ must lie between $2$ mg/L and $10$ mg/L. This is a clear increase from the day $1$ value of $EC_{50,1} = 2$ mg/L.\n    Let's assume the Hill coefficient remains $n_2 \\approx 1$ and $E_{max,2}=100$, and calculate a more precise $EC_{50,2}$. The model is $E(C) = \\frac{100 \\cdot C}{EC_{50,2} + C}$.\n    Using the point $(10, 63)$:\n    $$63 = \\frac{100 \\cdot 10}{EC_{50,2} + 10}$$\n    $$63 \\cdot (EC_{50,2} + 10) = 1000$$\n    $$63 \\cdot EC_{50,2} + 630 = 1000$$\n    $$63 \\cdot EC_{50,2} = 370$$\n    $$EC_{50,2} \\approx 5.87 \\text{ mg/L}$$\n    Let's test this value of $EC_{50,2} \\approx 6$ mg/L against the other data points:\n    - For $C=2$: $E = \\frac{100 \\cdot 2}{6 + 2} = \\frac{200}{8} = 25$. (Matches data)\n    - For $C=50$: $E = \\frac{100 \\cdot 50}{6 + 50} = \\frac{5000}{56} \\approx 89.3$. (Matches data value of $89$)\n    The fit is again excellent, confirming the parameters for Day 14: $E_{max,2} \\approx 100$, $EC_{50,2} \\approx 6$ mg/L, and $n_2 \\approx 1$.\n\n### Comparison and Conclusion\n- **Efficacy**: $E_{max,1} \\approx 100$ and $E_{max,2} \\approx 100$. Efficacy is unchanged.\n- **Potency**: $EC_{50,1} = 2$ mg/L and $EC_{50,2} \\approx 6$ mg/L. The $EC_{50}$ has increased. An increase in $EC_{50}$ signifies a decrease in potency.\n- **Hill Coefficient**: $n_1 \\approx 1$ and $n_2 \\approx 1$. The steepness of the curve is unchanged.\n\nThe development of tolerance is characterized by an increase in $EC_{50}$ with no change in $E_{max}$. This corresponds to a rightward shift of the concentration-effect curve, meaning higher concentrations are needed to achieve the same level of effect. This is a classic pattern of pharmacodynamic tolerance, often associated with competitive antagonism at the receptor level.\n\n## OPTION-BY-OPTION ANALYSIS\n\n**A. Tolerance decreases $E_{max}$ while $EC_{50}$ is unchanged.**\nOur analysis shows that $E_{max}$ is unchanged (not decreased) and $EC_{50}$ increases (is not unchanged). Both claims in this option are contrary to the data.\n**Verdict: Incorrect.**\n\n**B. Tolerance increases $EC_{50}$ while $E_{max}$ is unchanged.**\nOur analysis shows that $EC_{50}$ increased from approximately $2$ mg/L to $6$ mg/L, while $E_{max}$ remained constant at approximately $100$. This statement perfectly describes the observations.\n**Verdict: Correct.**\n\n**C. Tolerance decreases the Hill coefficient $n$ while $E_{max}$ and $EC_{50}$ are unchanged.**\nOur analysis shows the Hill coefficient $n$ is unchanged (approximately $1$ in both cases), not decreased. Furthermore, $EC_{50}$ is not unchanged; it increases. This option is incorrect on multiple points.\n**Verdict: Incorrect.**\n\n**D. Tolerance is purely pharmacokinetic (increased clearance), with no change in pharmacodynamics; the observed shift arises from lower concentrations at equal doses.**\nThis option describes pharmacokinetic tolerance. However, the problem provides measured concentration-effect data, $(C, E)$, and explicitly asks for an analysis of this relationship. The data shows that for a given concentration $C$ (e.g., $C=2$ mg/L), the effect $E$ is lower on day $14$ ($E=25$) than on day $1$ ($E=50$). This is, by definition, a change in pharmacodynamics (the relationship between $C$ and $E$). The premise of this option (\"no change in pharmacodynamics\") is directly falsified by the provided data. The problem setup intentionally isolates the pharmacodynamic changes from any potential pharmacokinetic changes.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Building on the identification of tolerance, this problem challenges you to address its clinical consequences. Patients can develop tolerance through multiple mechanisms simultaneously, including faster drug elimination (pharmacokinetic tolerance) and reduced receptor sensitivity (pharmacodynamic tolerance). This practice will guide you through a quantitative analysis to determine the necessary dose adjustment, demonstrating how to integrate different physiological changes into a coherent therapeutic strategy .",
            "id": "4944888",
            "problem": "A patient is maintained on a drug that produces a submaximal target effect through a saturable, monotonic concentration–effect relationship characterized by a potency parameter (the concentration producing one-half of the maximal effect) and an efficacy parameter (the maximal effect). Over time, the patient develops both pharmacokinetic tolerance (increased drug elimination) and pharmacodynamic tolerance (reduced sensitivity at the receptor-effector level).\n\nAssume the following:\n- The pharmacokinetics are linear and time-invariant over the dosing interval, and the system is at steady state.\n- The absolute bioavailability $F$ is unchanged.\n- The maintenance dosing regimen is adjusted only by scaling the maintenance dose rate, with dosing interval and route unchanged.\n- The pharmacokinetic tolerance doubles the systemic clearance from $CL$ to $2\\,CL$.\n- The pharmacodynamic tolerance shifts the potency parameter from $EC_{50}$ to $\\alpha\\,EC_{50}$ with $\\alpha > 0$, while the efficacy (maximal effect) and the Hill coefficient $n$ remain unchanged.\n- The concentration–effect relationship follows a standard saturable model with a Hill coefficient $n$.\n\nDetermine, in closed form, the fold-change factor by which the maintenance dose rate must be multiplied to maintain the same target effect at steady state as before tolerance developed. Express your answer as a symbolic expression in terms of $\\alpha$. The fold-change factor is dimensionless. No rounding is required, and no units should be included in the final boxed answer.",
            "solution": "The problem requires determining the fold-change in the maintenance dose rate needed to counteract the effects of both pharmacokinetic and pharmacodynamic tolerance, thereby maintaining a constant therapeutic effect.\n\nLet us define the initial state (pre-tolerance) and the final state (post-tolerance).\n\n**Initial State (Pre-Tolerance)**\n\nLet the initial maintenance dose rate be $R_1$. The initial systemic clearance is $CL_1 = CL$. The problem states that the system is at steady state. For linear pharmacokinetics at steady state, the average drug concentration, $C_{ss,1}$, is given by the ratio of the rate of drug administration available to the systemic circulation to the systemic clearance.\n$$C_{ss,1} = \\frac{F \\cdot R_1}{CL_1} = \\frac{F \\cdot R_1}{CL}$$\nHere, $F$ is the absolute bioavailability.\n\nThe concentration–effect relationship is described by the Hill equation:\n$$E = \\frac{E_{max} \\cdot C^n}{EC_{50}^n + C^n}$$\nwhere $E$ is the effect at concentration $C$, $E_{max}$ is the maximal effect, $EC_{50}$ is the concentration that produces $50\\%$ of the maximal effect (the potency parameter), and $n$ is the Hill coefficient.\n\nIn the initial state, the potency parameter is $EC_{50,1} = EC_{50}$. The target effect, $E_{target}$, is produced by the steady-state concentration $C_{ss,1}$.\n$$E_{target} = \\frac{E_{max} \\cdot (C_{ss,1})^n}{(EC_{50,1})^n + (C_{ss,1})^n} = \\frac{E_{max} \\cdot (C_{ss,1})^n}{EC_{50}^n + (C_{ss,1})^n}$$\n\n**Final State (Post-Tolerance)**\n\nLet the new maintenance dose rate be $R_2$.\nThe patient develops pharmacokinetic tolerance, which doubles the systemic clearance. The new clearance is $CL_2 = 2 \\cdot CL$.\nThe new steady-state concentration, $C_{ss,2}$, is:\n$$C_{ss,2} = \\frac{F \\cdot R_2}{CL_2} = \\frac{F \\cdot R_2}{2 \\cdot CL}$$\n\nThe patient also develops pharmacodynamic tolerance, where the potency parameter shifts. The new potency parameter is $EC_{50,2} = \\alpha \\cdot EC_{50}$. The maximal effect $E_{max}$ and the Hill coefficient $n$ remain unchanged.\n\nThe goal is to adjust the dose rate $R_2$ to maintain the same target effect, $E_{target}$. Therefore, the effect produced by $C_{ss,2}$ must be equal to the original $E_{target}$.\n$$E_{target} = \\frac{E_{max} \\cdot (C_{ss,2})^n}{(EC_{50,2})^n + (C_{ss,2})^n} = \\frac{E_{max} \\cdot (C_{ss,2})^n}{(\\alpha \\cdot EC_{50})^n + (C_{ss,2})^n}$$\n\n**Connecting the States and Solving**\n\nSince the target effect $E_{target}$ is the same in both states, we can equate the two expressions for $E_{target}$.\n$$\\frac{E_{max} \\cdot (C_{ss,1})^n}{EC_{50}^n + (C_{ss,1})^n} = \\frac{E_{max} \\cdot (C_{ss,2})^n}{(\\alpha \\cdot EC_{50})^n + (C_{ss,2})^n}$$\nThe $E_{max}$ term is common to both sides and can be cancelled (since $E_{max} \\ne 0$ for a meaningful effect).\n$$\\frac{(C_{ss,1})^n}{EC_{50}^n + (C_{ss,1})^n} = \\frac{(C_{ss,2})^n}{\\alpha^n EC_{50}^n + (C_{ss,2})^n}$$\nTo simplify, let's take the reciprocal of both sides.\n$$\\frac{EC_{50}^n + (C_{ss,1})^n}{(C_{ss,1})^n} = \\frac{\\alpha^n EC_{50}^n + (C_{ss,2})^n}{(C_{ss,2})^n}$$\nSeparating the terms gives:\n$$\\frac{EC_{50}^n}{(C_{ss,1})^n} + 1 = \\frac{\\alpha^n EC_{50}^n}{(C_{ss,2})^n} + 1$$\nSubtracting $1$ from both sides:\n$$\\frac{EC_{50}^n}{(C_{ss,1})^n} = \\frac{\\alpha^n EC_{50}^n}{(C_{ss,2})^n}$$\nSince $EC_{50} > 0$, we can cancel the term $EC_{50}^n$.\n$$\\frac{1}{(C_{ss,1})^n} = \\frac{\\alpha^n}{(C_{ss,2})^n}$$\nRearranging the terms:\n$$(C_{ss,2})^n = \\alpha^n (C_{ss,1})^n$$\nTaking the $n$-th root of both sides (since concentrations $C$ and parameter $\\alpha$ are positive real numbers):\n$$C_{ss,2} = \\alpha \\cdot C_{ss,1}$$\nThis result indicates that to overcome the pharmacodynamic tolerance (the reduced sensitivity), the new steady-state concentration must be $\\alpha$ times the original steady-state concentration.\n\nNow, we substitute the pharmacokinetic expressions for $C_{ss,1}$ and $C_{ss,2}$ into this relationship.\n$$C_{ss,1} = \\frac{F \\cdot R_1}{CL} \\quad \\text{and} \\quad C_{ss,2} = \\frac{F \\cdot R_2}{2 \\cdot CL}$$\nSubstituting these into $C_{ss,2} = \\alpha \\cdot C_{ss,1}$:\n$$\\frac{F \\cdot R_2}{2 \\cdot CL} = \\alpha \\cdot \\left( \\frac{F \\cdot R_1}{CL} \\right)$$\nThe terms $F$ and $CL$ are non-zero and appear on both sides, so they can be cancelled.\n$$\\frac{R_2}{2} = \\alpha \\cdot R_1$$\nWe are asked to find the fold-change factor by which the maintenance dose rate must be multiplied. This factor is the ratio $\\frac{R_2}{R_1}$.\n$$\\frac{R_2}{R_1} = 2\\alpha$$\nThis result shows that the required fold-change in the dose rate is the product of the factor needed to overcome the pharmacokinetic tolerance (a factor of $2$ to compensate for the doubled clearance) and the factor needed to overcome the pharmacodynamic tolerance (a factor of $\\alpha$ to achieve the higher concentration required for the same effect).\n\nFinal Answer Derivation:\n1.  The pharmacokinetic tolerance doubles clearance ($CL \\rightarrow 2CL$). To maintain the same concentration, the dose rate must double ($R \\rightarrow 2R$).\n2.  The pharmacodynamic tolerance increases $EC_{50}$ by a factor of $\\alpha$ ($EC_{50} \\rightarrow \\alpha EC_{50}$). To maintain the same fractional effect, the concentration must increase by a factor of $\\alpha$ ($C_{ss} \\rightarrow \\alpha C_{ss}$).\n3.  To increase the steady-state concentration by a factor of $\\alpha$, the dose rate must also increase by a factor of $\\alpha$ ($R \\rightarrow \\alpha R$), assuming constant clearance.\n4.  Combining these two independent effects, the total change in dose rate is the product of the individual factors. The new dose rate $R_2$ must be $2 \\times \\alpha$ times the original dose rate $R_1$.\nTherefore, the fold-change factor is $2\\alpha$.",
            "answer": "$$\n\\boxed{2\\alpha}\n$$"
        },
        {
            "introduction": "Long-term drug use can lead not only to tolerance but also to physiological dependence, where the body adapts to require the drug for normal functioning. This final exercise shifts our focus to modeling the clinically critical phenomenon of withdrawal that occurs upon drug cessation. You will develop a dynamic model to predict the onset and peak severity of withdrawal symptoms by considering the competing rates of drug elimination and the body's own gradual recovery process .",
            "id": "4944905",
            "problem": "A patient has developed physiological dependence on a full agonist of the mu-opioid receptor after long-term therapy and abruptly discontinues dosing at time $t=0$. You are asked to predict the timing of withdrawal onset and the time of peak withdrawal severity using only fundamental pharmacokinetic and pharmacodynamic principles.\n\nUse the following modeling base and definitions:\n\n1. The plasma concentration of the agonist, $C_{\\text{agon}}(t)$, follows first-order elimination with half-life $t_{1/2}$, so $C_{\\text{agon}}(t)$ decays exponentially from its value at $t=0$.\n2. The minimum agonist concentration required to avert withdrawal at time $t$, denoted $C_{\\text{thresh}}(t)$, relaxes back toward zero after cessation as a first-order recovery process that starts at $C_{\\text{thresh}}(0)=C_{w0}$ with rate constant $k_{a}$, reflecting reversal of receptor adaptation.\n3. A competitive antagonist is started at $t=0$ and maintained at a constant plasma concentration $I$. For competitive antagonism with inhibition constant $K_{i}$, the effective agonist concentration driving receptor signaling is reduced by a factor $\\beta = \\frac{1}{1+I/K_{i}}$ at all $t \\ge 0$.\n\nDefine withdrawal onset as the earliest time $t_{\\text{onset}}$ at which the effective agonist concentration equals the instantaneous threshold, and define the time of peak withdrawal severity, $t_{\\text{peak}}$, as the time at which the difference $C_{\\text{thresh}}(t)-\\beta\\,C_{\\text{agon}}(t)$ is maximized for $t \\ge 0$.\n\nGiven the data\n- $t_{1/2} = 12\\,\\text{h}$,\n- $C_{\\text{agon}}(0)=C_{0}=80\\,\\text{ng} \\cdot \\text{mL}^{-1}$,\n- $C_{w0}=10\\,\\text{ng} \\cdot \\text{mL}^{-1}$,\n- $k_{a}=0.040\\,\\text{h}^{-1}$,\n- $I=2.0\\,\\text{ng} \\cdot \\text{mL}^{-1}$,\n- $K_{i}=0.50\\,\\text{ng} \\cdot \\text{mL}^{-1}$,\n\ncalculate $t_{\\text{onset}}$ and $t_{\\text{peak}}$. Express both answers in hours and round your answers to three significant figures.",
            "solution": "First, we formulate the mathematical models for the agonist concentration and the withdrawal threshold based on the provided definitions.\n\nThe plasma concentration of the agonist, $C_{\\text{agon}}(t)$, is stated to follow first-order elimination kinetics. Its decay from the initial concentration at $t=0$, which is $C_{\\text{agon}}(0) = C_{0}$, is described by the exponential decay equation:\n$$C_{\\text{agon}}(t) = C_{0} \\exp(-k_e t)$$\nIn this equation, $k_e$ represents the first-order elimination rate constant. This constant is related to the agonist's half-life, $t_{1/2}$, by the standard formula:\n$$k_e = \\frac{\\ln(2)}{t_{1/2}}$$\n\nThe minimum agonist concentration required to prevent withdrawal, $C_{\\text{thresh}}(t)$, is modeled as a first-order recovery process. It relaxes exponentially from its initial value at $t=0$, $C_{\\text{thresh}}(0) = C_{w0}$, toward a baseline of zero. The equation for this process is:\n$$C_{\\text{thresh}}(t) = C_{w0} \\exp(-k_a t)$$\nHere, $k_a$ is the provided rate constant for the reversal of receptor adaptation.\n\nThe problem states that a competitive antagonist is administered at a constant plasma concentration $I$. The effect of this antagonist is to reduce the effective concentration of the agonist by a constant factor $\\beta$. This factor is defined by the principles of competitive antagonism:\n$$\\beta = \\frac{1}{1 + \\frac{I}{K_i}}$$\nwhere $K_i$ is the inhibition constant for the antagonist. Consequently, the effective agonist concentration at any time $t \\ge 0$ is given by the product $\\beta C_{\\text{agon}}(t)$.\n\nWithdrawal onset, denoted as $t_{\\text{onset}}$, is defined as the earliest time $t \\ge 0$ at which the effective agonist concentration precisely equals the instantaneous withdrawal threshold. We can express this condition mathematically as:\n$$\\beta C_{\\text{agon}}(t_{\\text{onset}}) = C_{\\text{thresh}}(t_{\\text{onset}})$$\nSubstituting the explicit functions for the concentrations yields:\n$$\\beta C_{0} \\exp(-k_e t_{\\text{onset}}) = C_{w0} \\exp(-k_a t_{\\text{onset}})$$\nTo solve for $t_{\\text{onset}}$, we first isolate the exponential terms:\n$$\\frac{\\beta C_{0}}{C_{w0}} = \\frac{\\exp(-k_a t_{\\text{onset}})}{\\exp(-k_e t_{\\text{onset}})} = \\exp((k_e - k_a) t_{\\text{onset}})$$\nWe then take the natural logarithm of both sides of the equation:\n$$\\ln\\left(\\frac{\\beta C_{0}}{C_{w0}}\\right) = (k_e - k_a) t_{\\text{onset}}$$\nProvided that $k_e \\neq k_a$, we can solve for $t_{\\text{onset}}$:\n$$t_{\\text{onset}} = \\frac{\\ln\\left(\\frac{\\beta C_{0}}{C_{w0}}\\right)}{k_e - k_a}$$\n\nNext, we determine the time of peak withdrawal severity, $t_{\\text{peak}}$. The severity of withdrawal at time $t$, denoted $S(t)$, is defined as the difference between the threshold concentration and the effective agonist concentration:\n$$S(t) = C_{\\text{thresh}}(t) - \\beta C_{\\text{agon}}(t) = C_{w0} \\exp(-k_a t) - \\beta C_{0} \\exp(-k_e t)$$\nTo find the time at which $S(t)$ is maximized, we must find the critical points by taking the first derivative of $S(t)$ with respect to time $t$ and setting it to zero.\n$$\\frac{dS}{dt} = \\frac{d}{dt} \\left[ C_{w0} \\exp(-k_a t) - \\beta C_{0} \\exp(-k_e t) \\right]$$\n$$\\frac{dS}{dt} = -k_a C_{w0} \\exp(-k_a t) - \\beta C_{0} (-k_e) \\exp(-k_e t)$$\n$$\\frac{dS}{dt} = k_e \\beta C_{0} \\exp(-k_e t) - k_a C_{w0} \\exp(-k_a t)$$\nSetting $\\frac{dS}{dt} = 0$ for $t = t_{\\text{peak}}$:\n$$k_e \\beta C_{0} \\exp(-k_e t_{\\text{peak}}) = k_a C_{w0} \\exp(-k_a t_{\\text{peak}})$$\nRearranging the terms to solve for $t_{\\text{peak}}$:\n$$\\frac{k_e \\beta C_{0}}{k_a C_{w0}} = \\frac{\\exp(-k_a t_{\\text{peak}})}{\\exp(-k_e t_{\\text{peak}})} = \\exp((k_e - k_a) t_{\\text{peak}})$$\nTaking the natural logarithm of both sides:\n$$\\ln\\left(\\frac{k_e \\beta C_{0}}{k_a C_{w0}}\\right) = (k_e - k_a) t_{\\text{peak}}$$\n$$t_{\\text{peak}} = \\frac{\\ln\\left(\\frac{k_e \\beta C_{0}}{k_a C_{w0}}\\right)}{k_e - k_a}$$\nThe existence of a maximum is confirmed by the second derivative test, which shows that $\\frac{d^2S}{dt^2}  0$ at this critical point if $k_e > k_a$.\n\nWe are given the following data:\n- $t_{1/2} = 12\\,\\text{h}$\n- $C_{0} = 80\\,\\text{ng} \\cdot \\text{mL}^{-1}$\n- $C_{w0} = 10\\,\\text{ng} \\cdot \\text{mL}^{-1}$\n- $k_a = 0.040\\,\\text{h}^{-1}$\n- $I = 2.0\\,\\text{ng} \\cdot \\text{mL}^{-1}$\n- $K_{i} = 0.50\\,\\text{ng} \\cdot \\text{mL}^{-1}$\n\nFirst, we compute the constants $k_e$ and $\\beta$:\n$$k_e = \\frac{\\ln(2)}{12\\,\\text{h}} \\approx 0.057762\\,\\text{h}^{-1}$$\n$$\\beta = \\frac{1}{1 + \\frac{2.0\\,\\text{ng} \\cdot \\text{mL}^{-1}}{0.50\\,\\text{ng} \\cdot \\text{mL}^{-1}}} = \\frac{1}{1 + 4} = \\frac{1}{5} = 0.20$$\nThe difference in the rate constants is $k_e - k_a \\approx 0.057762\\,\\text{h}^{-1} - 0.040\\,\\text{h}^{-1} = 0.017762\\,\\text{h}^{-1}$. This value is positive, confirming that a maximum exists for $S(t)$.\n\nFor the calculation of $t_{\\text{onset}}$:\nThe ratio inside the logarithm is:\n$$\\frac{\\beta C_{0}}{C_{w0}} = \\frac{0.20 \\times 80}{10} = \\frac{16}{10} = 1.6$$\nSubstituting the values into the formula for $t_{\\text{onset}}$:\n$$t_{\\text{onset}} = \\frac{\\ln(1.6)}{k_e - k_a} \\approx \\frac{0.470004}{0.017762}\\,\\text{h} \\approx 26.460\\,\\text{h}$$\nRounding to three significant figures, we get $t_{\\text{onset}} = 26.5\\,\\text{h}$.\n\nFor the calculation of $t_{\\text{peak}}$:\nThe argument of the logarithm is:\n$$\\frac{k_e \\beta C_{0}}{k_a C_{w0}} = \\frac{k_e}{k_a} \\times \\frac{\\beta C_{0}}{C_{w0}} \\approx \\frac{0.057762}{0.040} \\times 1.6 \\approx 1.44405 \\times 1.6 \\approx 2.31048$$\nSubstituting the values into the formula for $t_{\\text{peak}}$:\n$$t_{\\text{peak}} = \\frac{\\ln(2.31048)}{k_e - k_a} \\approx \\frac{0.83744}{0.017762}\\,\\text{h} \\approx 47.147\\,\\text{h}$$\nRounding to three significant figures, we get $t_{\\text{peak}} = 47.1\\,\\text{h}$.\n\nThus, the withdrawal symptoms are predicted to begin at approximately $26.5$ hours and reach their maximum severity at approximately $47.1$ hours after the last dose.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n26.5  47.1\n\\end{pmatrix}\n}\n$$"
        }
    ]
}